Antithrombotic therapy in heart failure: what conclusions can be drawn?
No prospective, randomized trials exist in which placebo, antiplatelet or anticoagulant therapy in patients with congestive heart failure have been compared. Most studies have looked retrospectively at the impact of these treatments on systemic embolism and the ensuing morbidity and mortality, and none of the large trails of heart failure was initially designed to address this question.
Cokkinos
D V
DV
Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece.
D000925:Anticoagulants / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D010919:Placebos; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D013927:Thrombosis / Q000517:prevention & control
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010919:Placebos; D010975:Platelet Aggregation Inhibitors